Synthesis,Green Chemistry Method Characterization of CuFe5O8 Nanocomposite and Assessment of Its Prostate Cancer-Preventive Effects
DOI:
https://doi.org/10.69923/IJAS.2024.010109Keywords:
CuFe5O8,, Nanoparticles,, Origanum,, Flutamide, , Prostate cancerAbstract
In this work, CuFe5O8 nanoparticles were prepared to utilize Origanum vulgare leaf extract in a novel, simple, and inexpensive procedure that incorporated three techniques: co-precipitation, ultrasound, and green chemistry. The following methods were used to characterize the produced nanoparticles: XRD, FT-IR, EDX, SEM, and DLS. The average particle size measured in the XRD was 45.101 nm, but the average particle size in the SEM was 64.17 nm. The DLS had particles with an average size of 924.4 nm simultaneously. The efficacy of the synthesised CuFe5O8 nanoparticles was evaluated against that of the medication Flutamide, which is administered to treat prostate cancer in Iraq using the PC3 cell line. The results demonstrated the nanoparticles' outstanding efficacy and superiority over the medication. In addition, they were distinguished by their lack of cytotoxicity when measured against the drug's toxicity on red blood cells in the toxicity screening test. If the results indicated that the drug Flutamide had a cell killing value of 6.51, 10.55, 27.69, 32.48, and 52.53) at 24 hours, as well as for CuFe5O8, respectively, the cell killing results were 33.69, 38.53, 46.42, 56.11, and 69.59)% as well value IC50 = 88.46.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Iraqi Journal for Applied Sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licenses and Copyright
The copyright of this article is retained by the author(s).
This article is published by the Iraqi Journal for Applied Science (IJAS) under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This license permits unrestricted use, distribution, reproduction, adaptation, and reuse of the work in any medium or format, including commercial use, provided that appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any modifications are indicated.
Authors retain full copyright of their work and grant IJAS a non-exclusive license to publish, archive, preserve, and disseminate the article, including registration of metadata and Digital Object Identifiers (DOIs) through Crossref.
Any third-party material included in this article remains subject to its respective copyright and licensing conditions. Authors are responsible for obtaining all necessary permissions for such material before publication.
For complete details regarding copyright, licensing, permissions, and reuse, please refer to the journal's Copyright and Licensing Policy available on the IJAS website.
License: https://creativecommons.org/licenses/by/4.0/



